{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T02:43:54Z","timestamp":1786589034990,"version":"build-2736575974"},"reference-count":107,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To provide a clinically oriented narrative review of recently reported human trial data on emerging pharmacotherapies for obesity and type 2 diabetes beyond glucagon\u2010like peptide\u20101 receptor agonist (GLP\u20101RA) monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This narrative review summarizes recent clinical evidence on incretin\u2010based and related therapeutic strategies, including dual and triple incretin\u2010 or glucagon\u2010based agonists, long\u2010acting amylin analogues, oral agents, and combination approaches targeting complementary satiety and metabolic pathways. The review focuses on human trial data and evaluates key outcomes including body weight reduction, glycemic control, body\u2010composition effects, tolerability, and broader cardiometabolic changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Incretin\u2010based therapies have transformed the management of obesity and type 2 diabetes, with GLP\u20101RAs achieving levels of weight loss that begin to narrow the gap with metabolic surgery in selected populations. Recent developments have substantially expanded the field beyond GLP\u20101RA monotherapy. Emerging agents now include multi\u2010agonists, amylin\u2010based therapies, novel oral compounds, and combination strategies designed to improve not only the magnitude of weight loss, but also its quality, durability, and metabolic consequences. Across trials, these approaches have shown promising effects on body weight, glycemic control, and selected cardiometabolic parameters, although differences in tolerability, evidence maturity, and practical feasibility remain important.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Current data indicate a rapid shift from single\u2010pathway interventions toward multimodal therapeutic strategies in obesity and type 2 diabetes. Future positioning of these agents within treatment algorithms will depend not only on efficacy, but also on long\u2010term safety, durability of effect, tolerability, adherence, access, and their impact on clinically meaningful outcomes beyond body weight alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70822","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T03:46:14Z","timestamp":1778211974000},"page":"5556-5589","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Beyond\n                    <scp>GLP<\/scp>\n                    \u20101 Monotherapy: Novel Multi\u2010Agonists, Amylin Analogues, and Combination Strategies in Obesity and Type 2 Diabetes"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7606-6565","authenticated-orcid":false,"given":"Mikhail","family":"Khachaturov","sequence":"first","affiliation":[{"name":"Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology Medical School, Aristotle University of Thessaloniki  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios G.","family":"Goulis","sequence":"additional","affiliation":[{"name":"Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology Medical School, Aristotle University of Thessaloniki  Thessaloniki Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2025.07.017"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc26-S005"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-0014"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-025-01125-9"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-024-01473-y"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_2_9_9_1","unstructured":"US Food and Drug Administration \u201cFDA approves fourth product under National Priority Voucher Program higher dose semaglutide \u201daccessed April 17 2026 https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010fourth\u2010product\u2010under\u2010national\u2010priority\u2010voucher\u2010program\u2010higher\u2010dose\u2010semaglutide."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00226-8"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2500969"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2026.0035"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01185-6"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01127-3"},{"key":"e_1_2_9_15_1","unstructured":"US Food and Drug Administration \u201cFDA approves first new molecular entity under National Priority Voucher Program \u201daccessed April 17 2026 https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010first\u2010new\u2010molecular\u2010entity\u2010under\u2010national\u2010priority\u2010voucher\u2010program."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511774"},{"key":"e_1_2_9_17_1","unstructured":"Eli Lilly and Company \u201cLilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP\u20101 therapy in first\u2010of\u2010its\u2010kind phase 3 trial \u201daccessed April 17 2026 https:\/\/investor.lilly.com\/news\u2010releases\/news\u2010release\u2010details\/lillys\u2010orforglipron\u2010helped\u2010people\u2010maintain\u2010weight\u2010loss\u2010after."},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107519"},{"key":"e_1_2_9_20_1","unstructured":"US Food and Drug Administration \u201cFDA approves first medication for obstructive sleep apnea \u201daccessed April 17 2026 https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010first\u2010medication\u2010obstructive\u2010sleep\u2010apnea."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00225-6"},{"key":"e_1_2_9_22_1","unstructured":"Eli Lilly and Company \u201cA study of investigational tirzepatide doses in participants with type 2 diabetes and obesity \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT06037252."},{"key":"e_1_2_9_23_1","unstructured":"C. B.Hanmi \u201cPharmaceutical reports efpeglenatide cuts weight up to 30% in Korean phase 3 trial \u201daccessed April 17 2026 https:\/\/biz.chosun.com\/en\/en\u2010science\/2025\/10\/27\/TFO77Y5HTVDPTOAQR25JS37Y34\/."},{"key":"e_1_2_9_24_1","unstructured":"Hanmi Pharmaceutical Company Limited \u201cA multicenter randomized double\u2010blind phase 3 study to evaluate efficacy and safety of HM11260C in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT07379333."},{"key":"e_1_2_9_25_1","unstructured":"Metsera Inc \u201cMetsera reports positive phase 2b results for first\u2010 and best\u2010in\u2010class ultra\u2010long acting GLP\u20101 RA candidate MET\u2010097i enabling rapid transition into phase 3 \u201daccessed April 17 2026 https:\/\/www.globenewswire.com\/news\u2010release\/2025\/09\/29\/3158095\/0\/en\/Metsera\u2010Reports\u2010Positive\u2010Phase\u20102b\u2010Results\u2010for\u2010First\u2010and\u2010Best\u2010in\u2010Class\u2010Ultra\u2010long\u2010Acting\u2010GLP\u20101\u2010RA\u2010Candidate\u2010MET\u2010097i\u2010Enabling\u2010Rapid\u2010Transition\u2010into\u2010Phase\u20103.html."},{"key":"e_1_2_9_26_1","unstructured":"Pfizer \u201cPfizer's ultra\u2010long\u2010acting injectable GLP\u20101 RA shows robust and continued weight loss with monthly dosing in phase 2b trial \u201daccessed April 17 2026 https:\/\/www.pfizer.com\/news\/press\u2010release\/press\u2010release\u2010detail\/pfizers\u2010ultra\u2010long\u2010acting\u2010injectable\u2010glp\u20101\u2010ra\u2010shows\u2010robust."},{"key":"e_1_2_9_27_1","unstructured":"Ascletis Pharma (China) Co. Limited \u201cA phase I\/IIa randomized double\u2010blind placebo\u2010controlled single and multiple ascending dose study to evaluate the safety tolerability and pharmacokinetics of ASC30 injection for subcutaneous use in participants with obesity \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT06679959."},{"issue":"1","key":"e_1_2_9_28_1","article-title":"750\u2010P: ASC30, an Oral GLP\u20101R Biased Small Molecule Agonist in Participants With Obesity\u2014A First\u2010In\u2010Human Single Ascending Dose Study","volume":"74","author":"Wu J. J.","year":"2025","journal-title":"Diabetes"},{"key":"e_1_2_9_29_1","unstructured":"J. J.WuandV.Wang \u201cASC30 an Oral GLP\u20101R Biased Small Molecule Agonist Demonstrated Superior Weight Loss in Participants with Obesity: A 28\u2010Day Multiple Ascending Dose Study \u201dhttps:\/\/www.ascletis.com\/data\/upload\/ueditor\/20250618\/Oral_presentation_ASC30_EASD_20250916_final_version.pdf."},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/db25-752-P"},{"key":"e_1_2_9_31_1","unstructured":"Boehringer Ingelheim \u201cA phase 3 randomised double\u2010blind parallel\u2010group 76\u2010week efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT06066515."},{"key":"e_1_2_9_32_1","unstructured":"Boehringer Ingelheim \u201cA phase 3 randomised double\u2010blind parallel\u2010group 76\u2010week efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT06066528."},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24184"},{"key":"e_1_2_9_34_1","unstructured":"Hengrui PharmaandKailera Therapeutics \u201cHengrui Pharma and Kailera Therapeutics report positive topline data from phase 3 obesity trial in China of dual GLP\u20101\/GIP receptor agonist HRS9531 \u201daccessed November 13 2025 https:\/\/www.kailera.com\/press\u2010release\/hengrui\u2010pharma\u2010and\u2010kailera\u2010therapeutics\u2010report\u2010positive\u2010topline\u2010data\u2010from\u2010phase\u20103\u2010obesity\u2010trial\u2010in\u2010china\u2010of\u2010dual\u2010glp\u20101\u2010gip\u2010receptor\u2010agonist\u2010hrs9531\/."},{"key":"e_1_2_9_35_1","unstructured":"Jiangsu Hansoh Pharmaceutical Co. Ltd \u201cA study of HS\u201020094 versus dulaglutide once weekly as add\u2010on therapy to metformin monotherapy or in combination with SGLT2 inhibitors in participants with type 2 diabetes \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT07156539."},{"key":"e_1_2_9_36_1","unstructured":"Regeneron Pharmaceuticals Inc \u201cRegeneron expands clinical\u2010stage obesity portfolio with strategic in\u2010licensing of novel dual GLP\u20101\/GIP receptor agonist \u201daccessed April 17 2026 https:\/\/investor.regeneron.com\/news\u2010releases\/news\u2010release\u2010details\/regeneron\u2010expands\u2010clinical\u2010stage\u2010obesity\u2010portfolio\u2010strategic\/."},{"issue":"1","key":"e_1_2_9_37_1","article-title":"Efficacy and Safety of BGM0504 in Chinese Patients With Type 2 Diabetes\u2014A Multicenter, Randomized, Double\u2010Blind, Placebo\u2010Controlled and Semaglutide Positive\u2010Controlled Phase 2 Trial","volume":"74","author":"303\u2010OR","year":"2025","journal-title":"Diabetes"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70006"},{"key":"e_1_2_9_39_1","unstructured":"Roche \u201cRoche announces positive phase II results for its dual GLP\u20101\/GIP receptor agonist CT\u2010388 in people living with obesity \u201daccessed April 17 2026 https:\/\/www.roche.com\/media\/releases\/med\u2010cor\u20102026\u201001\u201027."},{"key":"e_1_2_9_40_1","unstructured":"Hoffmann\u2010La Roche \u201cA phase III randomized double\u2010blind placebo\u2010controlled parallel\u2010group study to evaluate the efficacy and safety of once\u2010weekly RO7795068 administered to participants with obesity or overweight without type 2 diabetes \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT07351045."},{"key":"e_1_2_9_41_1","unstructured":"Hoffmann\u2010La Roche \u201cA phase III randomized double\u2010blind placebo\u2010controlled parallel\u2010group study to evaluate the efficacy and safety of once\u2010weekly RO7795068 administered to participants with obesity or overweight and type 2 diabetes \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT07351058."},{"key":"e_1_2_9_42_1","unstructured":"S. H.Hsia H.Bays L. K.Billings et\u00a0al. \u201cMazdutide (LY3305677) in participants with obesity or overweight: a phase 2 dose\u2010finding study \u201daccessed April 17 2026 https:\/\/assets.ctfassets.net\/mpejy6umgthp\/1y1DRY2Hmq1fxM6pJXLbsY\/5802adfaed34b59c6fcfccb2095ad9c7\/VV\u2010MAZPT3_OW2025_HSIA_MAZDUTIDE_SYMPOSIUM_DV\u2010037120_V4.7.pdf."},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411528"},{"key":"e_1_2_9_44_1","unstructured":"Innovent Biologics \u201cMazdutide 9\u2009mg Supplementary Application Accepted for Review by China's NMPA Potentially Offering a Novel Drug Option for Moderate\u2010To\u2010Severe Obese Population \u201daccessed April 17 2026 https:\/\/en.innoventbio.com\/InvestorsAndMedia\/PressReleaseDetail?key=564."},{"key":"e_1_2_9_45_1","unstructured":"Innovent Biologics \u201cInnovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head\u2010to\u2010head Phase 3 Clinical Trial DREAMS\u20103 \u201daccessed April 17 2026 https:\/\/en.innoventbio.com\/InvestorsAndMedia\/PressReleaseDetail?key=558."},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010025\u201010026\u2010w"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02114-2"},{"key":"e_1_2_9_48_1","unstructured":"The United Bio\u2010Technology (Hengqin) Co. Ltd \u201cA phase II clinical study to evaluate the efficacy and safety of UBT251 injection in obese\/overweight chronic kidney disease population \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT07134335."},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00092-0"},{"key":"e_1_2_9_50_1","unstructured":"Eli Lilly and Company \u201cLilly's triple agonist retatrutide delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful phase 3 trial \u201daccessed April 17 2026 https:\/\/investor.lilly.com\/news\u2010releases\/news\u2010release\u2010details\/lillys\u2010triple\u2010agonist\u2010retatrutide\u2010delivered\u2010weight\u2010loss\u2010average."},{"key":"e_1_2_9_51_1","unstructured":"Eli Lilly and Company \u201cLilly's triple agonist retatrutide demonstrated significant reductions in A1C and weight in first phase 3 trial for treatment of type 2 diabetes \u201daccessed April 17 2026 https:\/\/investor.lilly.com\/news\u2010releases\/news\u2010release\u2010details\/lillys\u2010triple\u2010agonist\u2010retatrutide\u2010demonstrated\u2010significant."},{"key":"e_1_2_9_52_1","unstructured":"Hanmi Pharmaceutical Company Limited. HM15275 \u201cObesityWeek poster \u201d2025 accessed April 17 2026 https:\/\/www.hanmi.co.kr\/science\u2010pdf\/HM15275\/2025_ObesityWeek_Poster_HM15275_218.pdf."},{"key":"e_1_2_9_53_1","unstructured":"Hanmi Pharmaceutical Company Limited \u201cA phase 2 randomized double\u2010blind placebo\u2010controlled parallel\u2010group study to evaluate efficacy safety and tolerability of HM15275 for 36\u2009weeks in obese or overweight subjects without diabetes mellitus \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT07205900."},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504214"},{"key":"e_1_2_9_55_1","unstructured":"Kailera Therapeutics \u201cKailera Therapeutics announces $600 million Series B financing to further advance pipeline of next\u2010generation therapies for the treatment of obesity \u201daccessed April 17 2026 https:\/\/investors.kailera.com\/news\u2010releases\/news\u2010release\u2010details\/kailera\u2010therapeutics\u2010announces\u2010600\u2010million\u2010series\u2010b\u2010financing."},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502081"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.125.26055"},{"key":"e_1_2_9_58_1","first-page":"1102","article-title":"Cagrilintide\u2010Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes","volume":"393","author":"Lingvay I.","year":"2025","journal-title":"New England Journal of Medicine"},{"key":"e_1_2_9_59_1","unstructured":"Novo Nordisk A\/S \u201cCagriSema demonstrated superior HbA1c reduction of 1.91%\u2010points and weight loss of 14.2% in adults with type 2 diabetes in the REIMAGINE 2 trial \u201daccessed April 17 2026 https:\/\/www.globenewswire.com\/news\u2010release\/2026\/02\/02\/3230429\/0\/en\/Novo\u2010Nordisk\u2010A\u2010S\u2010CagriSema\u2010demonstrated\u2010superior\u2010HbA1c\u2010reduction\u2010of\u20101\u201091\u2010points\u2010and\u2010weight\u2010loss\u2010of\u201014\u20102\u2010in\u2010adults\u2010with\u2010type\u20102\u2010diabetes\u2010in\u2010the\u2010REIMAGINE\u20102\u2010trial.html."},{"key":"e_1_2_9_60_1","unstructured":"Novo Nordisk \u201cCagriSema demonstrated 23% weight loss in an open\u2010label head\u2010to\u2010head REDEFINE 4 trial in people with obesity the primary endpoint was not achieved \u201daccessed April 17 2026 https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news\u2010and\u2010media\/news\u2010and\u2010ir\u2010materials\/news\u2010details.html?id=916501."},{"key":"e_1_2_9_61_1","unstructured":"Roche \u201cRoche announces positive phase II results for petrelintide an amylin analog developed for people living with overweight and obesity \u201daccessed April 17 2026 https:\/\/www.roche.com\/media\/releases\/med\u2010cor\u20102026\u201003\u201005."},{"key":"e_1_2_9_62_1","unstructured":"AstraZeneca \u201cA phase I randomized single\u2010blind placebo\u2010controlled study to evaluate the safety tolerability pharmacokinetics and pharmacodynamics of AZD6234 following repeat dose administration in participants with overweight or obesity \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT06132841."},{"key":"e_1_2_9_63_1","unstructured":"AstraZeneca \u201cA phase IIb randomised double\u2010blind placebo\u2010controlled study to evaluate the efficacy safety and tolerability of AZD6234 in participants living with obesity or overweight with comorbidity \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT06595238."},{"key":"e_1_2_9_64_1","unstructured":"AstraZeneca \u201cA phase IIb randomised double\u2010blind placebo\u2010controlled study to evaluate the efficacy safety and tolerability of co\u2010administration of AZD9550 and AZD6234 in participants living with obesity or overweight with co\u2010morbidity (ASCEND) \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT06862791."},{"key":"e_1_2_9_65_1","unstructured":"Gubra \u201cGubra announces positive GUBamy phase 1 interim MAD results \u201daccessed April 17 2026 https:\/\/www.gubra.dk\/mfn_news\/gubra\u2010announces\u2010positive\u2010gubamy\u2010phase\u20101\u2010interim\u2010mad\u2010results\/."},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2026.171480"},{"key":"e_1_2_9_67_1","unstructured":"Metsera \u201cA wholly owned subsidiary of Pfizer. A randomized double\u2010blind single and multiple ascending dose study to investigate the safety tolerability pharmacokinetics and pharmacodynamics of MET233 in otherwise healthy adult participants with obesity or overweight \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT07022977."},{"key":"e_1_2_9_68_1","unstructured":"Metsera \u201cA wholly owned subsidiary of Pfizer. A phase 1 randomized double\u2010blind placebo\u2010controlled single and multiple ascending dose study to investigate the safety tolerability pharmacokinetics and pharmacodynamics of MET233 co\u2010administered with MET097 in adult participants with obesity or overweight including participants with type 2 diabetes mellitus \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT06924320."},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02155-5"},{"key":"e_1_2_9_70_1","unstructured":"N.Nordisk \u201cNovo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes \u201daccessed April 17 2026 https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news\u2010and\u2010media\/news\u2010and\u2010ir\u2010materials\/news\u2010details.html?id=916463."},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505669"},{"key":"e_1_2_9_72_1","unstructured":"Eli Lilly and Company \u201cLilly's oral GLP\u20101 orforglipron demonstrated superior glycemic control in two successful Phase 3 trials reconfirming its potential as a foundational treatment in type 2 diabetes \u201daccessed April 17 2026 https:\/\/investor.lilly.com\/news\u2010releases\/news\u2010release\u2010details\/lillys\u2010oral\u2010glp\u20101\u2010orforglipron\u2010demonstrated\u2010superior\u2010glycemic."},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)00202-3"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)02165-8"},{"key":"e_1_2_9_75_1","unstructured":"A.Haggag L.Butcher X.Sun et\u00a0al. \u201cAZD5004\/ECC5004 A Small Molecule GLP\u20101 Receptor Agonist May Be Administered Once Daily under Fed\/Fasted Conditions \u201daccessed April 17 2026 https:\/\/www.eccogene.com\/wp\u2010content\/uploads\/OW\u20102024_ECC5004\u2010Food\u2010Effects\u2010Poster_FINAL_24Oct2024\u20101.pdf."},{"key":"e_1_2_9_76_1","unstructured":"AstraZeneca \u201cA phase IIb randomized double\u2010blind placebo\u2010controlled study to evaluate the efficacy safety and tolerability of AZD5004 in participants living with obesity or overweight with comorbidity \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT06579092."},{"key":"e_1_2_9_77_1","unstructured":"AstraZeneca \u201cA phase IIb randomized double\u2010blind placebo\u2010controlled and open\u2010label active comparator study to evaluate the efficacy safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT06579105."},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.2337\/db25-743-P"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.2337\/db25-837-P"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.2337\/db25-865-P"},{"key":"e_1_2_9_81_1","unstructured":"Structure Therapeutics \u201cStructure Therapeutics reports positive topline data from phase 2 ACCESS II trial with once\u2010daily oral small molecule GLP\u20101 receptor agonist aleniglipron \u201daccessed April 17 2026 https:\/\/structuretx.gcs\u2010web.com\/news\u2010releases\/news\u2010release\u2010details\/structure\u2010therapeutics\u2010reports\u2010positive\u2010topline\u2010data\u2010phase\u20102."},{"key":"e_1_2_9_82_1","unstructured":"TechTarget \u201cStructure announces mid\u2010stage data for its oral GLP\u20101 candidate \u201daccessed April 17 2026 https:\/\/www.techtarget.com\/pharmalifesciences\/news\/366636177\/Structure\u2010announces\u2010mid\u2010phase\u2010data\u2010for\u2010its\u2010oral\u2010GLP\u20101\u2010candidate."},{"key":"e_1_2_9_83_1","unstructured":"Viking Therapeutics \u201cViking Therapeutics announces positive top\u2010line results from phase 2 VENTURE\u2010Oral dosing trial of VK2735 tablet formulation in patients with obesity \u201daccessed April 17 2026 https:\/\/ir.vikingtherapeutics.com\/2025\u201008\u201019\u2010Viking\u2010Therapeutics\u2010Announces\u2010Positive\u2010Top\u2010Line\u2010Results\u2010from\u2010Phase\u20102\u2010VENTURE\u2010Oral\u2010Dosing\u2010Trial\u2010of\u2010VK2735\u2010Tablet\u2010Formulation\u2010in\u2010Patients\u2010with\u2010Obesity."},{"key":"e_1_2_9_84_1","unstructured":"Viking Therapeutics \u201cViking Therapeutics to Highlight Clinical Data From VK2735 Obesity Program in Presentations at ObesityWeek \u201d2025 accessed April 17 2026 https:\/\/ir.vikingtherapeutics.com\/2025\u201010\u201029\u2010Viking\u2010Therapeutics\u2010to\u2010Highlight\u2010Clinical\u2010Data\u2010from\u2010VK2735\u2010Obesity\u2010Program\u2010in\u2010Presentations\u2010at\u2010ObesityWeek\u2010R\u20102025."},{"key":"e_1_2_9_85_1","unstructured":"Biomed Industries \u201cBiomed Industries Unveils Promising Phase 2 Results of NA\u2010931 the First Oral Quadruple Agonist for Obesity at ENDO \u201d2025 accessed April 17 2026 https:\/\/www.biomedind.com\/news\u2010NA\u2010931\u2010ENDO2025.html."},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16534"},{"key":"e_1_2_9_87_1","unstructured":"Terns Pharmaceuticals \u201cTerns Pharmaceuticals reports topline 12\u2010week data from its phase 2 trial evaluating oral GLP\u20101 receptor agonist TERN\u2010601 in obesity \u201daccessed April 17 2026 https:\/\/ir.ternspharma.com\/news\u2010releases\/news\u2010release\u2010details\/terns\u2010pharmaceuticals\u2010reports\u2010topline\u201012\u2010week\u2010data\u2010its\u2010phase\u20102\/."},{"key":"e_1_2_9_88_1","unstructured":"Kailera Therapeutics \u201cEfficacy and Safety of Oral KAI\u20107535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight\u2010Related Comorbidity \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT07497880."},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.2337\/db25-785-P"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04204-0"},{"key":"e_1_2_9_91_1","unstructured":"Regeneron Pharmaceuticals \u201cA Randomized Double\u2010Blind Study of the Efficacy and Safety of Trevogrumab with or without Garetosmab in Addition to Semaglutide in Patients with Obesity \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT06299098."},{"key":"e_1_2_9_92_1","unstructured":"Regeneron Pharmaceuticals Inc \u201cResults from phase 2 COURAGE trial demonstrating potential to improve quality of GLP\u20101 receptor agonist\u2010induced weight loss by preserving lean mass presented at EASD \u201daccessed April 17 2026 https:\/\/investor.regeneron.com\/news\u2010releases\/news\u2010release\u2010details\/results\u2010phase\u20102\u2010courage\u2010trial\u2010demonstrating\u2010potential\u2010improve\/."},{"key":"e_1_2_9_93_1","unstructured":"Palatin Technologies \u201cPalatin announces MC4R agonist bremelanotide co\u2010administered with GLP\u20101\/GIP tirzepatide meets primary endpoint in phase 2 obesity study \u201daccessed April 17 2026 https:\/\/palatin.com\/press_releases\/palatin\u2010announces\u2010mc4r\u2010agonist\u2010bremelanotide\u2010co\u2010administered\u2010with\u2010glp\u20101\u2010gip\u2010tirzepatide\u2010meets\u2010primary\u2010endpoint\u2010in\u2010phase\u20102\u2010obesity\u2010study\/."},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24329"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00141-X"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-68165-7"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00196-2"},{"key":"e_1_2_9_98_1","unstructured":"Eli Lilly and Company \u201cA parallel\u2010group treatment phase 2 double\u2010blind study of once\u2010weekly subcutaneous LY3457263 compared to placebo in participants with type 2 diabetes mellitus on a stable dose of semaglutide or tirzepatide who failed to achieve HbA1c goal \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT06897475."},{"key":"e_1_2_9_99_1","unstructured":"Eli Lilly and Company \u201cA phase 2 parallel\u2010group double\u2010blind placebo\u2010controlled study to investigate weight reduction with macupatide and eloralintide alone or in combination in adult participants with obesity or overweight and with type 2 diabetes \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT07215559."},{"key":"e_1_2_9_100_1","unstructured":"Eli Lilly and Company \u201cA phase 2 randomized double\u2010blind placebo\u2010controlled proof\u2010of\u2010concept study of once\u2010weekly tirzepatide plus mibavademab compared with tirzepatide alone in adult participants with obesity \u201daccessed April 17 2026 https:\/\/clinicaltrials.gov\/study\/NCT06373146."},{"key":"e_1_2_9_101_1","unstructured":"Veru Inc \u201cVeru reports positive results from phase 2b QUALITY and maintenance extension study showing enobosarm significantly reduced body weight regain prevented fat regain and preserved lean mass after semaglutide discontinuation \u201daccessed April 17 2026 https:\/\/ir.verupharma.com\/news\u2010events\/press\u2010releases\/detail\/236\/veru\u2010reports\u2010positive\u2010results\u2010from\u2010phase\u20102b\u2010quality\u2010and."},{"key":"e_1_2_9_102_1","unstructured":"Veru Inc \u201cVeru enrolls first patient in phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss \u201daccessed April 17 2026 https:\/\/ir.verupharma.com\/news\u2010events\/press\u2010releases\/detail\/252\/veru\u2010enrolls\u2010first\u2010patient\u2010in\u2010phase\u20102b\u2010plateau\u2010clinical."},{"key":"e_1_2_9_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(25)00216-5"},{"key":"e_1_2_9_104_1","unstructured":"Skye Bioscience Inc \u201cSkye Bioscience late\u2010breaking oral abstract at ObesityWeek 2025 to highlight improvement in rebound weight gain \u201daccessed April 17 2026 https:\/\/ir.skyebioscience.com\/news\u2010releases\/detail\/246\/skye\u2010bioscience\u2010late\u2010breaking\u2010oral\u2010abstract\u2010at\u2010obesityweek\u20102025\u2010to\u2010highlight\u2010improvement\u2010in\u2010rebound\u2010weight\u2010gain."},{"key":"e_1_2_9_105_1","unstructured":"Skye Bioscience Inc \u201cSkye reports positive CBeyond phase 2a extension interim study results for nimacimab in combination with semaglutide \u201daccessed April 17 2026 https:\/\/ir.skyebioscience.com\/news\u2010releases\/detail\/253\/skye\u2010reports\u2010positive\u2010cbeyond\u2010phase\u20102a\u2010extension\u2010interim\u2010study\u2010results\u2010for\u2010nimacimab\u2010in\u2010combination\u2010with\u2010semaglutide."},{"key":"e_1_2_9_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.12.006"},{"key":"e_1_2_9_107_1","unstructured":"OrsoBio \u201cOrsoBio announces positive topline phase 1b\/2a clinical data for its oral mitochondrial protonophore TLC\u20106740 in combination with tirzepatide \u201daccessed April 17 2026 https:\/\/orsobio.com\/press\u2010release\/orsobio\u2010announces\u2010positive\u2010topline\u2010phase\u20101b\u20102a\u2010clinical\u2010data\u2010for\u2010its\u2010oral\u2010mitochondrial\u2010protonophore\u2010tlc\u20106740\u2010in\u2010combination\u2010with\u2010tirzepatide\/."},{"key":"e_1_2_9_108_1","unstructured":"Vivani Medical Inc \u201cVivani Medical announces rapid advancement of NPM\u2010139 a novel semaglutide implant following positive weight loss data from an ongoing preclinical study of NPM\u2010139 and promising results from the LIBERATE\u20101 phase 1 clinical study of NPM\u2010115 \u201daccessed April 17 2026 https:\/\/investors.vivani.com\/investors\/news\u2010events\/press\u2010releases\/detail\/198\/vivani\u2010medical\u2010announces\u2010rapid\u2010advancement\u2010of\u2010npm\u2010139\u2010a."}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70822","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.70822","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70822","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T07:35:39Z","timestamp":1786088139000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.70822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":107,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/dom.70822"],"URL":"https:\/\/doi.org\/10.1111\/dom.70822","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"2026-01-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}